tbuckley/cabot-search huggingface dataset:
FRI0337 Safety and efficacy of adalimumab in children with active polyarticular juvenile idiopathic arthritis aged 2 to &lt;4 years or ≥4 years weighing &lt;15 kg
Authors: D. Kingsbury, P. Quartier, S. Santra, H. Kupper, N. Mozaffarian
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU, and Japan. ADA has not been studied in pts &lt;4 yrs old, and limited data are available in pts ≥4 yrs old weighing &lt;15 kg. <h3>Objectives</h3> To assess safety and effectiveness of ADA in pts 2 to &lt;4 yrs old or ≥4 yrs old weighing &lt;15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA. <h3>Methods</h3> This is a multicenter, open-label, Phase 3b study in pts 2 to &lt;4 yrs old or ≥4 yrs weighing &lt;15 kg with moderately to severely active JIA in the US and EU. ADA was given subcutaneously every other wk, 24 mg/m<sup>2</sup> BSA up to 20 mg/dose, for a minimum of 24 wks or until pts reached 4 yrs old and weighed 15 kg. Concomitant use of DMARDs was allowed. Key effectiveness endpoints were the proportion of pts achieving PedACR30/50/70/90 at wk 24. Other outcomes were tender joint count (TJC), swollen joint count (SJC), Pain on Passive Motion (POM75), Limitation on Passive Motion (LOM69), Active Joint Count (AJC73), Child Health Assessment Questionnaire (DICHAQ), Physician’s Global Assessment of Disease (PhGA), and Parent’s Global Assessment (PaGA) of Disease and Pain. Adverse events (AE) are being collected throughout the treatment period and include safety data up to 96 wks. <h3>Results</h3> 88% of the pts were female. At baseline, mean age was 3 yrs, mean weight=13 kg, mean JIA duration=12 months, and 39% had elevated CRP (≥0.9 mg/dL). Of 32 pts enrolled, 31 completed 24 wks of treatment. At wk 24, 90% of pts had achieved PedACR30 (Table 1). Improvements in other JIA outcomes were also seen at wk 24 of ADA treatment (Table 2). AE incidence rates included: any AEs (84%, 27/32), serious AEs (16%, 5/32), infectious AEs (69%, 22/32), and serious infections (9%, 3/32); no deaths, malignancies, opportunistic infections/TB, congestive heart failure, demyelinating disease, allergic reactions, lupus-like syndrome, or blood dyscrasias were reported. <h3>Conclusions</h3> Adalimumab was safe and effective in younger JIA patients (2 to &lt;4 yr old or ≥4 yrs old weighing &lt;15 kg) with active polyarticular disease, with a safety profile similar to that seen in older pediatric patients with JIA. <h3>Disclosure of Interest</h3> D. Kingsbury Grant/Research support from: Abbott, P. Quartier Grant/Research support from: Abbott, Novartis, Pfizer, Consultant for: Abbott, S. Santra Shareholder of: Abbott, Employee of: Abbott, H. Kupper Shareholder of: Abbott, Employee of: Abbott, N. Mozaffarian Shareholder of: Abbott, Employee of: Abbott
SAT0481 Clinical Factors for Incident Vertebral Fractures Treated with Bisphosphonates in Glucocorticoid-Induced Osteoporosis. Who Needs to Use Other Anti-Osteoporotic Agents?
Authors: M. Ushikubo, H. Kuda, H. Ito, K. Izumi, S. Tamaki, K. Akiya, I. Tanaka, H. Oshima
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Although bisphosphonates (BP) is a popular choice for prevention and treatment of Glucocorticoid-induced osteoporosis (GIO), other agents such as teriparatide (TPT) or denosmab have been also available for the treatment. Based on an aspect of health economics, BP would be a first lime of the choice for prevention and treatment of GIO. On the other hands, the effect of TPT was reduced when TPT was started after a long term treatment of BP. Therefore, it would be best if we distinguish a population that did not receive the anti-osteoporotic effect of BP. <h3>Objectives</h3> To clarify clinical factors which correlated with incident fractures in patients treated with BP, and distinguish patients who need other anti-osteoporotic agents. <h3>Methods</h3> Patients (n=137) with connective tissue diseases other than rheumatoid arthritis were recruited and observed for 2 years. The means of age, disease duration, total prednisolone (PSL) dosage, and daily PSL dosage during the study period were 61±15 (SD), 12±11 years, 34±34g, and 8±6mg/day, respectively. Prevalent vertebral fractures were seen in 44% of the patients. Agents used for prevention and treatments of GIO were BP (54%), active vitamin D3 (7%), vitamin K2 (6%). Bone mineral densities (BMD) were measured with DXA at the distal radius. <h3>Results</h3> 1) Incident vertebral fractures determined with deteriorating grades by the SQ method were seen in 64 patients (47%). 2) Logistic regression analysis showed the age (1.43 (OR)/5yo), total PSL dosage (1.09/5g), daily PSL dosage (2.36/5mg), and BMD (1.25/5% decrease) as independent risk factors, and treatments with BP (0.02) and vitamin K2 (0.06) as preventing factors (P&lt;0.05). 3) Analysis of 74 patients with BP, incident fractures were seen in 22 patients (30%). Among those patients with incident fractures, the age was higher and the BMD was lower than those without incident fractures. Multivariable analysis with logistic regression revealed the presence of prevalent fracture (OR3.6), the higher daily PSL dosage during the study period (OR1.7/5mg), and the lower BMD (OR1.6/5%) as independent risk factors. <h3>Conclusions</h3> Patients treated with BP in GIO, the presence of prevalent fractures, the higher daily PSL dosages, and the lower BMD were risk factors for incident vertebral fractures. An further treatment may be needed in those patients. <h3>References</h3> Nawata et al. J Bone Miner Metab 23:105-109. Saag et al. Arthritis Rheum 60:33-46. Grossman et al. Athritis Care Res 62:1515-1526. Ettinger et al. J Bone Miner Res 19:745-751. Abrahamsen et al. Osteoporos Int 24: 321-328. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4798
Capsule retention in a patient with eosinophilic gastroenteritis mimicking diaphragm disease of the small bowel
Authors: S. Pasha, J. Leighton, J. Williams, G. De Petris, K. Harold, A. Shiff
Journal: Endoscopy (2009)

A 32-year-old man presented for evaluation of anemia, abdominal bloating, and weight loss. He had been diagnosed with eosinophilic gastroenteritis (EGE) in childhood. He had no history of current or past nonsteroidal anti-inflammatory drug (NSAID) use. Computed tomography enterography (CTE) did not reveal any small-bowel abnormalities. Video capsule endoscopy was significant for ulcerated stenoses similar to diaphragm disease ([Fig. 1]), and the test was complicated by capsule retention.
A lesson learnt: Never again
Authors: D. Abbas
Journal: BMJ (1998)

need for resuscitation does not concur with the BRESUS study.Those healthcare workers who talk to patients about resuscitation and who teach resuscitation to professionals and lay people need to take into account the influence of the media on the public's preconceived ideas about the efficacy and outcome of resuscitation.We thank Karen Wilson (World Productions), Suzi Brown (Granada), and Christine Harmer-Brown (BBC).
Abstract P5-01-08: Preoperative Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (18F-FDG) Compared with Conventional Assessment in Patients with Early Primary Breast Cancer: Preliminary Results of a Prospective Study
Authors: MB Petersen, AK Berthelsen, V Timmermans-Wielenga, N Kroman, T Binderup, UB Tange, M Andersson, A Kjaer, A Loft, J. Graff
Journal: Cancer Research (2010)

Abstract Background: The prognosis and clinical management of patients with newly diagnosed breast cancer depends on the extent of disease. The aim of this study was to compare the diagnostic and therapeutic impact of preoperative PET/CT, using 18F-FDG in the initial extra-axillary staging of patients with early breast cancer, to the results of conventional assessment. One hundred patients are planned enrolled. We here report the results of the first fifty consecutive patients. Patients and methods: Fifty consecutive patients with newly diagnosed early operable breast cancer with tumors ≥2 cm were examined preoperatively with conventional assessment (mammography, breast/axilla ultrasound, chest x-ray and blood samples) and PET/CT. Conventional assessment and PET/CT were evaluated independently with no prior knowledge of the other. Distant metastases/new primary cancers found on PET/CT were confirmed histologically, by other imaging modalities or with at least 1 year of follow-up. Results: The mean age was 56 ± 11 years. PET/CT identified primary tumor in all but two patients (96%). Nine cases of extra-axillary lymph node involvement were solely revealed by PET/CT in the internal mammary chain (n=7) and the supraclavicular region (n=2). Additionally, PET/CT solely detected distant metastasis (ovary, bone) in two patients and new primary cancers (ovary, lung) in another two patients. Two patients (4%) had non-malignant focal uptake of 18F-FDG confirmed with histologic biopsies (schwannoma, colon adenoma). In 12 patients (24%) extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 20% (10/50) of patients and ultimately a modification of planned treatment in 4 (8%) patients. No patient was down staged by PET/CT. Conclusion: PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative 18F-FDG-PET/CT has a substantially impact on initial staging and on clinical management in patients with early stage breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-01-08.
251 WNT-PATHWAY ACTIVATION IN TWO MOLECULAR CLASSES OF HEPATOCELLULAR CARCINOMA AND EXPERIMENTAL MODULATION BY SORAFENIB
Authors: A. Lachenmayer, C. Alsinet, R. Savic, L. Cabellos, S. Toffanin, Y. Hoshida, A. Villanueva, B. Minguez, P. Newell, H.-W. Tsai, J. Barretina, S. Thung, S.C. Ward, J. Bruix, V. Mazzaferro, M. Schwartz, S.L. Friedman, J.M. Llovet
Journal: Journal of Hepatology (2012)
SAT0088 Identification of Patients at High Risk for Death in Rheumatic Disease
Authors: S. Kleinert, M. Breunig, H.-P. Tony, M. Feuchtenberger, C. Kneitz, S. Lehmann, C. E. Angermann, G. Ertl, S. Störk
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with rheumatic diseases (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion of this risk increase seems explained by traditional cardiovascular risk factors. It is therefore difficult to identify patients with RD at high risk. <h3>Objectives</h3> We aimed to identify high risk patients for CV diseases and mortality by a screening program that is suitable for clinical practice in rheumatology. <h3>Methods</h3> 612 consecutive patients attending the rheumatology outpatient department of the University Hospital underwent a comprehensive CV risk assessment including history taking, patient questionnaires, ECG, and laboratory measurements including natriuretic peptides (NTproBNP). Screening was regarded positive if any of the following was present: European CV disease risk assessment Score (SCORE) ≥3% or NTproBNP≥200 pg/ml or any pathological ECG pattern. <h3>Results</h3> The patient population comprised patients with rheumatoid arthritis (RA, n=359) or various systemic autoimmune diseases (SAID, n=253) including connective tissue disease (n=157) and vasculitis (n=32). SCORE was ≥3% in 31%, 20% of the patients had a NTproBNP level ≥200 pg/ml, and 16% had a pathological ECG. Patients were followed for a median of 5.5 years. The figure shows KM-plots for the 3 screening strategies, and unadjusted hazard ratios with 95%CI. In an age- and sex-adjusted multivariable model, only NTproBNP≥200 pg/ml conferred independent prognostic information with HR 2.4 (1.10-5.39, P=0.028) and an area under the ROC curve of 82%. <h3>Image/graph</h3> <h3>Conclusions</h3> RD patients at high risk for death can be identified using simple screening tools. Particularly, patients with a SCORE ≥3% or NTproBNP ≥200 pg/ml are at high risk for death, justifying further diagnostics and closer long-term follow-up. <h3>Disclosure of Interest</h3> None Declared
Public Response To Reagan's Colon Cancer
Authors: W. Fenner
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Public Response To Reagan's Colon Cancer Get access Wendy Fenner Wendy Fenner Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 22, 15 November 1989, Pages 1694–1695, https://doi.org/10.1093/jnci/81.22.1694-a Published: 15 November 1989
Strategies for Making More Organs Available for Transplantation
Authors: Bruno Gridelli, Giuseppe Remuzzi
Journal: New England Journal of Medicine (2000)

Organ transplantation has evolved rapidly from the first early successes1 to the current widespread use of donated organs for the treatment of end-stage kidney, heart, and liver failure. With limited supplies of organs and an increasing demand for them, however, many patients who need transplants do not receive them (Figure 1).2 Each year, about 3000 patients in the United States die while waiting for an organ transplant, and about 100,000 potential candidates for transplantation die before they are placed on a waiting list.2 There is an 11 percent annual increase in the number of patients placed on waiting lists for . . .
I-123 Uptake in the Chest Wall After Needle Biopsy of a Pulmonary Nodule
Authors: SLEIMAN Y. NADDAF, MUSTAFA F. AKISIK, WALID S. OMAR, IVEN YOUNG, HUSSEIN M. ABDEL-DAYEM
Journal: Clinical Nuclear Medicine (1997)

McDougall listed 42 cases of physiologic and pathologic causes of abnormal distribution of radioiodine that can be misinterpreted for metastatic cancer in whole-body I-131 scans. The authors previously presented infected sebaceous cyst in the scalp as a cause of false-positive I-123 uptake. The authors use I-123 for routine thyroid scanning and for total-body search for metastatic thyroid cancer. The authors report one more false-positive result caused by oozing in the chest wall from the biopsy site for a pulmonary nodule.
The Randomized Registry Trial
Authors: Stuart G Baker, Barnett S Kramer, Karen S Lindeman
Journal: New England Journal of Medicine (2014)

To the Editor: Lauer and D'Agostino (Oct. 24 issue)1 noted the “intellectual trap” between randomized trials that lack external validity (generalizability) and observational studies that lack internal validity owing to unmeasured confounders. They propose registry-based randomized trials to achieve both internal and external validity. Unfortunately, such trials are not feasible if there is no registry or if randomization is unacceptable. For short-term end points, a much simpler, although less rigorous, alternative is the paired availability design.2–4 This method can be used to estimate treatment effect through comparison of outcomes in all patients before and after increased availability of the . . .
Changes in the Scope of Care Provided by Primary Care Physicians
Authors: Robert F. St. Peter, Marie C. Reed, Peter Kemper, David Blumenthal
Journal: New England Journal of Medicine (1999)

Strategies to control medical costs and improve the quality of care often translate into decisions affecting the range of services primary care physicians provide to patients, which patients are referred for specialty care, and the points in disease processes at which referrals are made. This study focused on physicians' assessments of changes in the scope of care provided by primary care physicians and their assessments of the appropriateness of the scope of the care that primary care physicians are expected to provide.
BI-11 * PROGNOSTIC microRNAS IN MALIGNANT GLIOMA
Authors: J. Hayes, H. Thygesen, A. Droop, M. Boissinot, C. Bellamy, T. Hughes, D. Westhead, L. Shaw, H. Wurdak, S. Lawler, S. Short
Journal: Neuro-Oncology (2014)

MicroRNAs are short non-coding RNAs that act as micro-managers of cellular function. Their dysregulation is well documented in many cancers. TCGA microRNA expression data is available to identify the prognostic potential of microRNAs in malignant glioma. Using the LASSO statistical approach for 475 glioblastomas in the TCGA dataset we identified a nine-microRNA signature that predicts overall (p = 2.26e-09) and progression-free survival (p = 9.91e-08) with superior power than conventional molecular markers, including MGMT methylation status. This signature has significance in all molecular subtypes of glioblastoma with the exception of the non-G-CIMP proneural group and validated in a separate validation cohort (p = 4.50E-02). The signature also predicts survival in grade II and III disease (p = 5.20e-03). The great majority of microRNAs in the signature have previously been shown to play a role in glioma biology. In addition, when we compared patient groups at the extremes of survival in grade III astrocytoma (poor prognosis n = 10, survival <18 months; good prognosis n = 6, survival > 48 months) and glioblastoma (poor prognosis n = 14, survival <4 months; good prognosis n = 13, survival > 48 months), we found that microRNA profiles aligned with specific neuro-developmental pathways were associated with outcomes. Specifically, poorer prognosis disease was associated with profiles aligned towards glial-restricted and oligodendrocyte precursor (OP) cells. Furthermore, correlation of microRNA expression patterns of OPs with expression of 39 grade III astrocytomas and 558 glioblastomas predicts survival with high significance (p= 5.50e-06), indicating that the more tightly a grade III or IV tumor correlates with an OP profile, the poorer the outcome. These observations indicate that microRNAs have predictive power in malignant glioma. MicroRNA expression patterns may also reveal important aspects of underlying tumor biology. This data, coupled with the superior stability of microRNAs over mRNAs in clinical specimens, suggests they may represent attractive candidates as novel biomarkers for the disease.
Meta-analysis of holmium laser enucleation versus transurethral resection of prostate for patients with benign prostatic obstruction
Authors: O. Naser, A. Negida, E. Kasem, A. Mokhtar, A. Menshawy, T. Badawy, A.S. Turky, A. Tammam, A. El-Sawaf, B. Gana
Journal: International Journal of Surgery (2015)
Jonathan Mann Edward James Barrington-Ward Nellie Eirwen Davies James Watson Farquhar Alexander Bruce Junor Gilbert Kandiah Mahadeva Stephen Lane Henderson Smith Dorothy Mary Yoxall
Authors: J. Leaning, P. J Adams, F W Beswick, G. Stark, R. Lampard, D. Wallooppillai, S. Thanabalasundrum, R. H. Smith, H. Yoxall
Journal: BMJ (1998)

In the crash of Swissair Flight 111 the world lost a major force in the battle against AIDS and social injustice.Jonathan Mann was born in Boston and earned his undergraduate degree in history from Harvard University in 1969, having spent much of his third year in Paris at the Ecole de Science Politique, where he met his first wife, Marie-Paule Bondat.His interest turned to medicine, and he entered
FRI0057 Sonographic characterization of subclinical synovitis in patients with rheumatoid arthritis in clinical remission. preliminary results.
Authors: J. Ramírez García, V. Ruíz-Esquide, I. Pomés, R. Celis, J. Pomés, S. Cabrera, R. Sanmartí, J. D. Cañete
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To identify and characterize subclinical synovitis in patients with rheumatoid arthritis (RA) in clinical remission using Power Doppler Ultrasound and immunohistology <h3>Methods</h3> Prospective study with a 12- month follow-up. We will select patients with RA who are in clinical remission (defined as DAS28 &lt;2.6) as evaluated by two rheumatologists. Clinical, epidemiological, demographic and serological data will be analyzed. Patients will undergo ultrasonography of both knees and hands (wrists, metacarpophalangeal [MCP], proximal interphalangeal [PIP], flexor and extensor tendons of the hand). Sonography findings were quantified as follows: synovial hypertrophy (grades 0-3) and power Doppler signal (grades 0-3). A portable ultrasound scanner (Esaote MyLab25) with a linear probe of 12 MHz was employed. Patients with <i>active synovitis</i> (synovial hypertrophy plus power doppler signal) will undergo synovial biopsy by arthroscopy or ultrasound-guided, depending on the size of the target joint. The correlation of Power Doppler signal, vascular patterns, the cellular infiltrate and cytokine expression in synovial tissue with the development of bone erosions assessed by MRI at 12 months will be performed, in order to identify prognostic markers. The ultimate goal is to recruit a total of 100 patients and 60 synovial biopsies. We here present the ultrasound results in the patients recruited so far. <h3>Results</h3> 42 patients have been recruited so far (35 women and 7 men with a mean age of 54 + -12.2 years and a mean disease duration of 117.3 + -88.3 months). Sixty-seven per cent and 76.2% of patients were positive for RF and ACPA, respectively. All patients were treated with DMARD and 42.9% were also in biological treatment. 88.1% of patients had synovial hypertrophy and 66.7% had Power Doppler signal. The most affected joint (with power Doppler signal) was the wrist (33.3%), followed by the 2nd MCP (9.6%). Patients with active synovitis had DAS28 (mean 2.26 versus 1.93, P = 0.016) and weight (mean 68.5 kg versus 59.3 kg, P = 0.018) significantly higher than patients without Power Doppler signal. No significant differences between patients treated with DMARDs and biologic therapy were found. <h3>Conclusions</h3> These preliminary results show that two-thirds of patients with RA in clinical remission exhibit power Doppler signal. The DAS28 was significantly higher in patients with active synovitis. No differences were found regarding baseline treatment. <h3>Disclosure of Interest</h3> None Declared
New Diagnostics Unveil Cancers By Visual and Molecular Means
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article New Diagnostics Unveil Cancers By Visual and Molecular Means Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 18, 18 September 1991, Pages 1285–1287, https://doi.org/10.1093/jnci/83.18.1285 Published: 18 September 1991